Centers & Labs

Home > Research > Centers & Labs > Medical Sciences Innovation Hub Program > Healthcare and Medical Data Multi-level Integration Platform Group >

Medical Sciences Innovation Hub Program

Cancer Immunology Data Multi-level Integration Unit

Unit Leader: Kazuhiro Kakimi (M.D., Ph.D.)
Kazuhiro  Kakimi(M.D., Ph.D.)

Main Research Field

Medicine, dentistry, and pharmacy

Related Research Fields

Biological Sciences / Biology

Keywords

  • Tumor Immunology
  • Immune regulation
  • Immunotherapy
  • Biomarker
  • Neoantigen

Selected Publications

  1. Nagaoka K, Hosoi A, Iino T, Morishita Y, Matsushita H, Kakimi K.:
    “Dendritic cell vaccine induces antigen-specific CD8(+) T cells that are metabolically distinct from those of peptide vaccine and is well-combined with PD-1 checkpoint blockade.”
    Oncoimmunology 7, e1395124 (2017)
  2. Hosoi A, Takeda K, Nagaoka K, Iino T, Matsushita H, Ueha S, Aoki S, Matsushima K, Kubo M, Morikawa T, Kitaura K, Suzuki R, Kakimi K.:
    “Increased diversity with reduced "diversity evenness" of tumor infiltrating T-cells for the successful cancer immunotherapy.”
    Sci Rep. 8, 1058 (2018)
  3. Matsushita H, Hasegawa K, Oda K, Yamamoto S, Nishijima A, Imai Y, Asada K, Ikeda Y, Karasaki T, Fujiwara K, Aburatani H, Kakimi K.:
    “The frequency of neoantigens per somatic mutation rather than overall mutational load or number of predicted neoantigens per se is a prognostic factor in ovarian clear cell carcinoma.”
    Oncoimmunology 6, e1338996 (2017)
  4. Karasaki T, Nagayama K, Kuwano H, Nitadori JI, Sato M, Anraku M, Hosoi A, Matsushita H, Morishita Y, Kashiwabara K, Takazawa M, Ohara O, Kakimi K, Nakajima J.:
    “An Immunogram for the Cancer-Immunity Cycle: Towards Personalized Immunotherapy of Lung Cancer.”
    J Thorac Oncol. 12, 791-803 (2017)
  5. Karasaki T, Nagayama K, Kuwano H, Nitadori JI, Sato M, Anraku M, Hosoi A, Matsushita H, Takazawa M, Ohara O, Nakajima J, Kakimi K.:
    “Prediction and prioritization of neoantigens: integration of RNA sequencing data with whole-exome sequencing.”
    Cancer Sci. 108, 170-177 (2017)
  6. Matsushita H, Sato Y, Karasaki T, Nakagawa T, Kume H, Ogawa S, Homma Y, Kakimi K.:
    “Neoantigen Load, Antigen Presentation Machinery, and Immune Signatures Determine Prognosis in Clear Cell Renal Cell Carcinoma.“
    Cancer Immunol Res. 4, 463-71 (2016)
  7. Karasaki T, Nagayama K, Kawashima M, Hiyama N, Murayama T, Kuwano H, Nitadori J, Anraku M, Sato M, Miyai M, Hosoi A, Matsushita H, Kikugawa S, Matoba R, Ohara O, Kakimi K, Nakajima J.:
    “Identification of Individual Cancer-Specific Somatic Mutations for Neoantigen-Based Immunotherapy of Lung Cancer.”
    J Thorac Oncol 11, 324-33 (2016)
  8. Kurose K, Ohue Y, Wada H, Iida S, Ishida T, Kojima T, Doi T, Suzuki S, Isobe M, Funakoshi T, Kakimi K, Nishikawa H, Udono H, Oka M, Ueda R, Nakayama E.:
    “Phase Ia Study of FoxP3+ CD4 Treg Depletion by Infusion of a Humanized Anti-CCR4 Antibody, KW-0761, in Cancer Patients.”
    Clin Cancer Res. 21, 4327-36 (2015)
  9. Matsushita H, Enomoto Y, Kume H, Nakagawa T, Fukuhara H, Suzuki M, Fujimura T, Homma Y, Kakimi K.:
    “A pilot study of autologous tumor lysate-loaded dendritic cell vaccination combined with sunitinib for metastatic renal cell carcinoma.”
    J Immunother Cancer. 2, 30 (2014)
  10. Matsushita H, Hosoi A, Ueha S, Abe J, Fujieda N, Tomura M, Maekawa R, Matsushima K, Ohara O, Kakimi K.:
    “Cytotoxic T lymphocytes block tumor growth both by lytic activity and IFNγ-dependent cell-cycle arrest.”
    Cancer Immunol Res 3, 26-36 (2015)

Contact information

Nihonbashi 1-chome Mitsui Building, 15th floor
1-4-1 Nihonbashi Chuo-ku, Tokyo
103-0027, Japan
Tel: +81-(0)3-6225-2246

Email: kazuhiro.kakimi [at] riken.jp

Related links

Home > Research > Centers & Labs > Medical Sciences Innovation Hub Program > Healthcare and Medical Data Multi-level Integration Platform Group >